Biotechnology firm Telomir Pharmaceuticals, Inc. reported preclinical findings that its lead compound, Telomir‑1, exhibited superior performance to the U.S. Food and Drug Administration-approved iron chelator Deferoxamine (DFO) in reducing intracellular ferrous iron (Fe²⁺) levels in a human keratinocyte (HaCaT) cell line. According to the company, the compound achieved a strong, dose- and time-dependent reduction at sub-micromolar concentrations, outperforming DFO across equivalent treatment conditions.
The study used live-cell imaging with the FerroOrange fluorescent probe to monitor intracellular iron content. The treated HaCaT cells were exposed to Telomir-1 or DFO, and fluorescence microscopy at three, six and sixteen hours showed markedly lower iron signal in the Telomir-1 arms compared with DFO at the same concentrations. The company described this as evidence of robust cell penetration and iron-modulating activity.
Telomir Pharmaceuticals described the scientific context by noting that intracellular iron and copper imbalance can drive reactive oxygen species (ROS) formation, epigenetic enzyme dysregulation (including the KDM2, KDM5 and KDM6 families) and genomic instability—processes relevant to aging, cancer and degenerative disease. The company said Telomir-1 is formulated as “Telomir-Zn” to effect a controlled intracellular metal exchange: binding excess reactive iron/copper while supplying bioavailable zinc to support enzymatic and antioxidant systems.
While the results were presented as promising, the company noted that the data remain limited to in-vitro human cell line studies and do not yet extend to animal or human clinical trials. Further preclinical investigation will be required to confirm efficacy, safety and translation into disease-relevant models.
